| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 31 Jul 2021 |  Dividend | ₹ 0.20 /share | 29 Jul 2021 | 133.40 | 120.65 |
| 13 Sept 2022 | Dividend | ₹ 1.80 /share | 12 Sept 2022 | 75.60 | 73.60 |
| 03 Aug 2023 | Dividend | ₹ 2.20 /share | 03 Aug 2023 | 65.02 | 80.63 |
| 05 Aug 2024 | Dividend | ₹ 2.40 /share | 05 Aug 2024 | 88.29 | 146.75 |
| 12 Aug 2024 |  Annual General Meeting | NA | 12 Aug 2024 | 104.16 | 144.07 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 122.59 | 134.38 |
| 07 Feb 2025 | Quarterly Result Announcement | NA | 07 Feb 2025 | 110.15 | 116.55 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 99.96 | 104.35 |
| 05 Aug 2025 | Dividend | ₹ 2.40 /share | 05 Aug 2025 | 104.35 | 114.45 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 112.25 | 108.90 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 119.45 | 108.90 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 100.42 | 99.73 |
Alembic
99.07
+0.12
(0.12%)
Key Fundamentals
Market Cap
2,543.94 Cr
EPS
12.10
PE Ratio
7.84
Dividend Yield
2.43 %
Industry
Realty 52 Week High
153.39
52 Week Low
85.46
PB Ratio
1.00
Debt to Equity
0.01
Actual
Company News
View All News
Alembic Pharmaceuticals secured USFDA final approval for Diltiazem Hydrochloride Tablets in four strengths, a cardiovascular therapy for high blood pressure and angina treatment. The approval brings the company's total ANDA approvals to 230, while shares closed 1.28% lower at Rs 904.20 and have declined 14% in 2025.
Alembic Limited Reports Mixed Q2 FY26 Results with Consolidated Revenue at Rs 5,586 Lakhs
10 days ago
10 days agoAlembic Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The company reported consolidated revenue from operations of Rs 5,586 lakhs for the quarter, compared to Rs 5,291 lakhs in the same period last year. Net profit after tax stood at Rs 4,780 lakhs for the quarter versus Rs 6,077 lakhs in the previous year. For the half year, consolidated revenue reached Rs 10,561 lakhs against Rs 10,370 lakhs last year, while net profit was Rs 9,269 lakhs compared to Rs 12,386 lakhs in the corresponding period. The company operates two main business segments: Active Pharmaceutical Ingredients Business and Real Estate Business. Earnings per share for the quarter was Rs 5.00 compared to Rs 4.71 in the same quarter last year. The Board meeting was held on November 10, 2025, commencing at 4:00 p.m. and concluding at 4:45 p.m.
Alembic Pharma Targets 18-20% EBITDA Margins Through Production Ramp-Up and New LaunchesNov 05, 2025
Nov 05, 2025Alembic Pharmaceuticals aims to increase its EBITDA margins to 18-20% over the next couple of years from the current 17%, according to Managing Director Pranav Amin. The company expects margin improvement through enhanced capacity and production ramp-up in the second half of the financial year. Alembic has allocated Rs 400 crore for capex, primarily for maintenance and de-bottlenecking. Despite ongoing pricing pressure in the US market, the company is countering this through higher volumes and new product additions. The generics segment outside the US has shown consistent growth over 15-20 quarters and represents a high-margin opportunity. Alembic plans high-value launches in the US market over the next 12-18 months, including complex injectables, peptides, and ophthalmic products. The company's shares closed 2.79% higher at Rs 950 on the NSE.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
731.15 | #1 1,80,982.66 | 42.79 | 8,995.90 | 29.28 | 2,695 | -14.56 | 39.30 | |
1,180.10 | 1,17,827.49 | 36.03 | #1 14,169.80 | 35.34 | #1 2,767 | 86.67 | 50.76 | |
1,691.50 | 72,858.02 | 87.65 | 7,735.50 | -17.93 | 617 | 94.97 | 51.06 | |
2,097.50 | 63,178.03 | 41.57 | 6,967.00 | 60.74 | 1,389 | 20.73 | 41.45 | |
1,698.90 | 60,751.18 | 43.68 | 3,964.50 | -3.54 | 1,302 | 31.45 | 53.37 | |
1,667.80 | 60,641.58 | #1 27.77 | 5,474.20 | 13.60 | 2,226 | 29.00 | 47.61 | |
902.10 | 22,054.82 | 27.78 | 5,313.50 | 4.92 | 681 | 47.96 | 35.10 | |
613.60 | 21,062.47 | 45.14 | 2,100.30 | 38.11 | 422 | 30.75 | 45.17 | |
1,536.50 | 16,428.92 | 112.08 | 4,162.80 | 29.36 | 95 | #1 177.78 | 46.76 | |
1,120.00 | 15,737.20 | 203.08 | 2,638.00 | #1 99.15 | 101 | -1,216.67 | 60.74 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
39.80 %
Net Income Growth
55.65 %
Cash Flow Change
280.65 %
ROE
45.41 %
ROCE
42.24 %
EBITDA Margin (Avg.)
8.02 %
Corporate Action
Technical Indicators
RSI(14)
Neutral 44.36
ATR(14)
Less Volatile 2.25
STOCH(9,6)
Neutral 47.86
STOCH RSI(14)
Neutral 38.57
MACD(12,26)
Bullish 0.03
ADX(14)
Weak Trend 12.68
UO(9)
Bearish 39.63
ROC(12)
Downtrend And Accelerating -2.94
WillR(14)
Neutral -79.61
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
